Dec 6, 2022
Certis Biologicals names new VP to focus on innovation efforts
Certis Biologicals has named a new vice president in an effort to sharpen its focus on innovation through partnerships, licensing and potential acquisitions.
Mike Allan is now the Columbia, Maryland-based biotechnology company’s vice president of business development and licensing. Allan joined Certis Biologicals in 2018 as vice president, North America.
“There is staggering investment in the agriculture space right now, and biologicals are at the forefront of many of those innovation efforts,” Amy O’Shea, Certis Biologicals president and CEO, said. “With our strong commitment to science, the internal innovation possible at our laboratory facilities, and our access to the market, we believe that we are a strong partner for emerging technology players. Mike’s industry breadth and respect will be key in leveraging these strengths for the overall growth of the sector.”
Prior to joining Certis, Allan served as president, North America of Isagro USA and in various roles at Arysta/Tomen, including global business development manager.
“Certis Biologicals has always been committed to bringing new technologies to the marketplace so that growers can feel comfortable protecting their crops and the environments in which they grow,” Allan said. “We have successfully launched many of these new advancements by leveraging partnerships with external collaborators such as W. Neudorff GmbH KG, Kaken Pharmaceutical Co. LTD and Novozymes. Dedication to this effort will bring vast opportunity to our innovation pipeline and to growers around the world who need additional crop protection tools.”
With operations in more than 50 countries, Certis Biologicals develops, manufactures and markets biological solutions for use in commercial agriculture, professional greenhouse and consumer markets.